Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

660
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
660
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

411
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
411
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

685
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
685
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

483
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
483
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

658
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
658
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

304
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking social media metrics: Daily interaction valence and well-being in university students.

The British journal of social psychology·2026
Same author

Perspectives on the Teaching and Learning of Non-Verbal Communication Skills: Tutor, Simulated Patient and Student Experiences of a Rapid Transition to Online Learning.

Medical science educator·2026
Same author

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.

Journal of medicinal chemistry·2026
Same author

Future Medical Doctors Are Not Learning About Overweight and Obesity in Children: Curriculum Analysis at Five Australian Medical Schools.

Medical science educator·2026
Same author

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

Future oncology (London, England)·2025
Same author

Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025

Related Experiment Video

Updated: Dec 6, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.5K

Carboplatin and hypomagnesemia: Is it really a problem?

Gregory Gaughran1, Kiran Qayyum2, Lillian Smyth2

  • 1Department of Medical Oncology, The Canberra Hospital, Canberra, Australian Capital Territory, Australia.

Asia-Pacific Journal of Clinical Oncology
|October 14, 2020
PubMed
Summary

Hypomagnesemia is common in ovarian cancer patients treated with carboplatin chemotherapy. A significant minority experienced severe hypomagnesemia, with risk factors including pre-existing low magnesium and gastrointestinal issues.

Keywords:
carboplatinchemotherapyhypomagnesemiaovarian cancer

More Related Videos

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
08:51

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

1.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Related Experiment Videos

Last Updated: Dec 6, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.5K
Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
08:51

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

1.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Carboplatin is preferred over cisplatin for ovarian cancer due to lower toxicity.
  • Hypomagnesemia is a known side effect of carboplatin, but its frequency and severity are not well-documented.

Purpose of the Study:

  • To determine the incidence and severity of hypomagnesemia in ovarian cancer patients receiving carboplatin.
  • To investigate potential dose-response relationships and confounding factors associated with hypomagnesemia.

Main Methods:

  • Retrospective review of ovarian cancer patients treated with carboplatin between 2012-2018.
  • Collected data on patient/disease characteristics, potential confounders, carboplatin dose, electrolytes, and magnesium replacement.

Main Results:

  • 72% of patients experienced hypomagnesemia; 11% had grade 2 and 11% had grade 3/4 severity.
  • Hypomagnesemia was associated with longer treatment duration, pre-existing hypomagnesemia, vomiting, diarrhea, and certain medications.
  • 14% of hypomagnesemia events did not resolve, indicating potential long-term renal toxicity risk.

Conclusions:

  • Hypomagnesemia is frequent in ovarian cancer patients on carboplatin, with a notable percentage experiencing severe cases.
  • High-risk groups include patients with premorbid hypomagnesemia, gastrointestinal issues, or on specific medications.
  • Further research is needed to clarify clinical relevance and the impact of interventions for hypomagnesemia.